CA3230996A1 - Methods for treating neurogenerative diseases - Google Patents
Methods for treating neurogenerative diseases Download PDFInfo
- Publication number
- CA3230996A1 CA3230996A1 CA3230996A CA3230996A CA3230996A1 CA 3230996 A1 CA3230996 A1 CA 3230996A1 CA 3230996 A CA3230996 A CA 3230996A CA 3230996 A CA3230996 A CA 3230996A CA 3230996 A1 CA3230996 A1 CA 3230996A1
- Authority
- CA
- Canada
- Prior art keywords
- methyl
- pyrimidin
- pyrrolo
- amine
- chloro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163260942P | 2021-09-07 | 2021-09-07 | |
| US63/260,942 | 2021-09-07 | ||
| PCT/US2022/075966 WO2023039368A1 (en) | 2021-09-07 | 2022-09-06 | Methods for treating neurogenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3230996A1 true CA3230996A1 (en) | 2023-03-16 |
Family
ID=85506882
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3230996A Pending CA3230996A1 (en) | 2021-09-07 | 2022-09-06 | Methods for treating neurogenerative diseases |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240382491A1 (https=) |
| EP (1) | EP4398986A4 (https=) |
| JP (1) | JP2024533263A (https=) |
| CN (1) | CN118251225A (https=) |
| CA (1) | CA3230996A1 (https=) |
| MX (1) | MX2024002886A (https=) |
| WO (1) | WO2023039368A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202108519TA (en) | 2019-02-13 | 2021-09-29 | Ptc Therapeutics Inc | Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia |
| WO2020167624A1 (en) | 2019-02-13 | 2020-08-20 | Ptc Therapeutics, Inc. | Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012012656A2 (en) * | 2010-07-21 | 2012-01-26 | University Of South Florida | Materials and methods for treating neurodegenerative diseases |
| EP2867236B1 (en) * | 2012-06-29 | 2017-06-14 | Pfizer Inc | Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors |
| CA2973949C (en) * | 2015-01-16 | 2023-07-11 | The General Hospital Corporation | Compounds for improving mrna splicing |
| WO2020167624A1 (en) | 2019-02-13 | 2020-08-20 | Ptc Therapeutics, Inc. | Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia |
-
2022
- 2022-09-06 CN CN202280074005.1A patent/CN118251225A/zh active Pending
- 2022-09-06 WO PCT/US2022/075966 patent/WO2023039368A1/en not_active Ceased
- 2022-09-06 US US18/689,624 patent/US20240382491A1/en active Pending
- 2022-09-06 MX MX2024002886A patent/MX2024002886A/es unknown
- 2022-09-06 EP EP22868236.5A patent/EP4398986A4/en active Pending
- 2022-09-06 JP JP2024514641A patent/JP2024533263A/ja active Pending
- 2022-09-06 CA CA3230996A patent/CA3230996A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4398986A1 (en) | 2024-07-17 |
| WO2023039368A1 (en) | 2023-03-16 |
| CN118251225A (zh) | 2024-06-25 |
| JP2024533263A (ja) | 2024-09-12 |
| MX2024002886A (es) | 2024-05-24 |
| US20240382491A1 (en) | 2024-11-21 |
| EP4398986A4 (en) | 2025-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4288441A1 (en) | Methods for treating spinocerebellar ataxia type 3 | |
| US12398140B2 (en) | Substituted pyrrolo [2,3-d]pyrimidines for treating familial dysautonomia | |
| WO2023250316A1 (en) | Compounds for treating spinocerebellar ataxia type 3 | |
| US10787433B2 (en) | Pyridazine derivatives as EAAT2 activators | |
| WO2022169868A1 (en) | Compounds for treating spinocerebellar ataxia type 3 | |
| US11377436B2 (en) | EAAT2 enhancing molecules | |
| US12286420B2 (en) | EAAT2 activators and methods of using thereof | |
| CA3230996A1 (en) | Methods for treating neurogenerative diseases | |
| EP4398987A1 (en) | Methods for treating neurogenerative diseases | |
| EP4398988A1 (en) | Methods for treating neurogenerative diseases | |
| US20240051968A1 (en) | Methods for treating spinocerebellar ataxia type 3 | |
| US20240041886A1 (en) | Methods for treating spinocerebellar ataxia type 3 | |
| US20240376111A1 (en) | Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease | |
| HK40042691A (en) | Eaat2 activators and methods of using thereof | |
| HK40042691B (en) | Eaat2 activators and methods of using thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240826 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240826 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240826 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R113 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS OR METHOD OF CORRESPONDENCE REQUEST RECEIVED Effective date: 20241015 |
|
| R18 | Changes to party contact information recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R18-R143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF ADDRESS REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241121 Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R18-R114 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF METHOD OF CORRESPONDENCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241121 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241121 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250820 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250820 |